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Whereas interleukin-10 (IL-10) is an anti-inflammatory cytokine known to regulate macrophage activation,
its full mechanism of action remains incompletely defined. In a screen to identify novel IL-10-induced genes,
we cloned the mouse ortholog of human ABIN-3 (also termed LIND). ABIN-3 expression was induced selec-
tively by IL-10 in both mouse and human mononuclear phagocytes coordinately undergoing proinflammatory
responses. In contrast to the previously characterized ABINs, mouse ABIN-3 was incapable of inhibiting
NF-B activation by proinflammatory stimuli. Generation and analysis of ABIN-3-null mice demonstrated that
ABIN-3 is unnecessary for the anti-inflammatory effects of IL-10 as well as for proper negative regulation of
NF-B. Conversely, human ABIN-3 was capable of inhibiting NF-B activation in response to signaling from
Toll-like receptor, IL-1, and tumor necrosis factor. Enforced expression of human ABIN-3 in human monocytic
cells suppressed the cytoplasmic degradation of IB, the activation of NF-B, and the induction of proin-
flammatory genes. Comparative sequence analyses revealed that mouse ABIN-3 lacks a complete ABIN
homology domain, which was required for the functional activity of human ABIN-3. ABIN-3 is, thus, an
IL-10-induced gene product capable of attenuating NF-B in human macrophages yet is inoperative in mice
and represents a basis for species-specific differences in IL-10 actions.
The proinflammatory functions of monocytes and macro-
phages represent an important component of host responses to
infection. These responses occur, in part, as a consequence of
the interaction between pathogen-associated molecular pat-
terns (PAMPs) expressed by infectious agents and cellular
pathogen recognition receptors (PRRs) expressed by the host.
PRRs are a large and diverse group of microbial sensors that
include the membrane-associated Toll-like receptors (TLRs)
and the cytoplasmic NOD-like receptors and RIG-like heli-
cases (1, 38, 46). In macrophages, engagement of a PRR by its
PAMP ligand, e.g., bacterial lipopolysaccharide (LPS), pepti-
doglycan (PGN), or viral double-stranded RNA, leads to trig-
gering of mitogen-activated protein kinase (MAPK) signaling
cascades and activation of transcription factors belonging to
the NF-B, the AP-1, and the IRF families (1, 40, 58). These
signaling processes effect the induction of genes that promote
the inflammatory response including cytokines, chemokines,
and enzymes responsible for producing reactive oxygen and
nitrogen species.
The cytokine interleukin-10 (IL-10) plays a critical role in
limiting the magnitude and duration of inflammatory re-
sponses (13, 39). This conclusion is supported by the finding
that mice lacking an IL-10 response display exacerbated in-
flammatory responses and develop a chronic inflammatory
bowel disease clinically related to Crohn’s disease (28, 56, 59).
Despite the clearly established physiologic relevance of IL-10’s
anti-inflammatory properties, its mechanism of action remains
incompletely understood. This subject is particularly complex
because IL-10 has been reported to exert its anti-inflammatory
functions through multiple mechanisms that include inhibition
of gene transcription, destabilization of mRNA, and suppres-
sion of protein translation (2, 8, 10, 12, 16, 26, 27, 41, 67). Some
of these effects have been reported to reflect the ability of
IL-10 to antagonize PRR-induced signaling and thereby inhibit
the activation of NF-B and p38 MAPK (17, 27, 53, 62). How-
ever, these mechanisms appear insufficient to account for the
breadth of IL-10’s biological effects. Additionally, the extent to
which IL-10 mediates its effects via cell- or species-specific
mechanisms of action remains unclear.
It is now generally accepted that IL-10 manifests its anti-
inflammatory effects by binding to a specific heterodimeric cell
surface receptor (consisting of the IL-10R1 and IL-10R2
polypeptides), resulting in the activation of the receptor-asso-
ciated tyrosine kinases JAK1 and Tyk2 and the latent tran-
scription factor STAT3 (13, 39). STAT3 activation was shown
to be obligatory for IL-10’s anti-inflammatory effects on both
mouse and human mononuclear phagocytes (51, 59, 65). Mice
lacking STAT3 specifically in macrophages and neutrophils
display an overexuberant inflammatory response phenotype
similar to that of mice lacking either IL-10 or the IL-10R2
receptor subunit (59, 64). Based on the findings that STAT3
and new protein synthesis are required for IL-10 function,
several groups performed large-scale gene microarray analyses
of human and mouse myeloid cells to identify IL-10-regulated
genes (25, 31, 47, 66). At present, relatively few of the IL-10-
induced genes identified thus far have been examined for their
role in mediating IL-10 action (16, 42, 67). The genes that have
been proposed to be functionally important appear to act se-
lectively in specific IL-10-dependent anti-inflammatory func-
tions, and as a result, no single IL-10-induced gene acts as a
master regulator of the cytokine’s broad effects.
Using a representational difference analysis (RDA) ap-
proach, we cloned a novel gene product that was induced in
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mouse macrophages by the combination of IL-10 and LPS
and was homologous in sequence to human LIND (Listeria
INDuced). LIND had been previously identified as a gene prod-
uct of unknown function expressed in human monocytes during
Listeria monocytogenes infection and, based on sequence ho-
mology, was also termed the third member of the ABIN (A20-
binding inhibitor of NF-B activation) family of proteins, i.e.,
ABIN-3 (21, 57). Because previously characterized members of
the ABIN family are capable of inhibiting NF-B activation in
response to particular stimuli in vitro (20, 24, 35, 61), we
addressed the question of whether the IL-10-inducible ABIN-3
protein we identified in mouse macrophages possessed an anti-
inflammatory effector function. Herein we show that IL-10, in
combination with proinflammatory stimuli, such as LPS, leads
to optimal induction of ABIN-3 expression in both mouse and
human mononuclear phagocytes. Although enforced expres-
sion of mouse ABIN-3 in cells had no effect on the activation
and function of the NF-B pathway, expression of the human
ortholog indeed suppressed both NF-B activation and induc-
tion of proinflammatory gene expression. This functional dis-
parity was due, in part, to the absence of an intact ABIN
homology domain in mouse ABIN-3. These results identify a
novel divergence between IL-10’s actions on human and mouse
cells, which may have significant mechanistic or functional
consequences for anti-inflammatory function between different
species.
MATERIALS AND METHODS
Reagents. Recombinant cytokines were obtained from the following sources:
mouse IL-10 (Schering-Plough), human IL-10 (eBioscience), mouse IL-6 and
human IL-1 (R&D Systems), mouse IL-1 (UCB/Celltech), human alpha in-
terferon A/D (IFN-A/D; Hoffman-LaRoche), and mouse and human tumor
necrosis factor alpha (TNF-) (Genentech). The IL-10 receptor-neutralizing
antibody (IL-10R1 monoclonal antibody [MAb], clone 1B13A) was provided by
Schering-Plough. LPS (from Escherichia coli 0127:B8), PGN (from Staphylococ-
cus aureus), and poly(I:C) were obtained from Sigma. Phosphorothioate-stabi-
lized CpG oligodeoxynucleotide (5-TCC ATG ACG TTC CTG ACG TT) (19)
and non-CpG oligodeoxynucleotide (5-CCA TGG CCA TGG CCA TGG) (15)
were obtained from IDT.
Cell culture and mice. The mouse monocyte/macrophage RAW264.7 and
the human epithelial HEK 293T cell lines were cultured in complete Dul-
becco’s minimum essential medium with 10% fetal calf serum. The human
monocytic cell lines THP-1 and U937 were cultured in complete RPMI 1640
medium supplemented with 10% fetal calf serum and 50 M 2-mercaptoeth-
anol. Mouse bone marrow-derived macrophages (BMM) were prepared as
described previously (9). IL-10-null mice were obtained from the Jackson
Laboratory and bred alongside wild-type mice in a specific-pathogen-free
facility in accordance with American Association of Laboratory Animal Sci-
ence guidelines.
Cloning of mouse ABIN-3 and ABIN-3. RAW264.7 cells were stimulated with
either LPS (50 ng/ml) alone or LPS plus IL-10 (100 ng/ml) for 2 h, and RDA was
performed as described previously (23, 43). After three sequential rounds of
subtraction using tester/driver ratios of 1:50, 1:400, and 1:800, final PCR products
were cloned into pBluescript II SK. A  phage cDNA library was constructed
(Uni-ZAP-XR; Stratagene) from LPS plus IL-10-stimulated RAW264.7 and
screened with an RDA-derived probe, yielding full-length mouse ABIN-3 and
ABIN-3 cDNA.
Plasmid constructs and antibodies. The cDNAs for mouse ABIN-3Long
(GenBank accession no. AK033534), ABIN-1, ABIN-2, Toll-like receptor 2
(TLR2), TLR3, TLR4, MD2, and CD14 were amplified by reverse transcription
(RT)-PCR from BMM-derived total RNA using SuperScript RT (Invitrogen)
and Pfu Turbo (Stratagene). Similarly, the cDNAs for human ABIN-3, ABIN-3,
RIP1, TRAF6, IKK, IKK, and RelA were subcloned from human leukocyte-
derived cDNA (BD Clontech). The mouse A20 cDNA was kindly provided by
David Goeddel (Amgen, San Francisco, CA). The human ABIN-3 mutants
	AHD1 (amino acids [aa] 1 to 151 fused to aa 173 to 325), 	AHD2 (aa 1 to 198
fused to aa 222 to 325), and 	AHD1/2 (aa 1 to 151 fused to aa 222 to 325) were
constructed by PCR and blunt-end ligation. For protein expression, cDNAs were
subcloned into pcDNA3 (Invitrogen) or the retroviral green fluorescent protein
(GFP)-RV vector (44, 50). For antibody generation, glutathione S-transferase
fusion proteins containing sequences specific for mouse ABIN-3 (aa 141 to 208)
or mouse ABIN-3 (aa 141 to 168) or common to both isoforms (aa 17 to 89)
were bacterially expressed, and hamster MAbs against ABIN-3 (T1C1H10) and
ABIN-3 (Tgr21A5) were produced.
Gene targeting. ABIN-3 (encoded by the gene Tnip3; official symbol
9030611K07Rik) genomic clones were isolated from a 129/Sv genomic library
(Lambda FIX II; Stratagene). The 5 homology arm represented a 1.6-kb NcoI-
NcoI fragment located upstream of exon 1 and was subcloned into the NotI-
linearized TNLOX1-3 gene-targeting vector (49). The 3 homology arm repre-
sented a 6.0-kb SacII-SalI fragment located downstream of exon 5 and was
subcloned into the AscI-PmeI site of the vector. The resulting vector was linear-
ized and electroporated into the MC-50 embryonic stem (ES) cell line (55). Two
hundred and sixty-seven ES clones doubly resistant to G418 and ganciclovir were
screened for homologous recombination by PCR and Southern blotting with 5
and 3 external probes. Three correctly targeted clones were identified and,
following in vitro Cre-mediated excision of the neomycin resistance gene, two
clones transmitted the mutant allele to produce independent lines of ABIN-3-
null mice (129/Sv background).
Retroviral vector transduction. For retrovirus packaging, HEK 293T cells
were transfected with 2.5 g GFP-RV vector (empty or containing an N-terminal
Myc epitope-tagged human ABIN-3 ortholog [hABIN-3]), 2.0 g pUMVC3-gag-
pol, and 0.5 g VSVg expression plasmids. THP-1 cells were infected in retro-
viral supernatant supplemented with 4 g/ml Polybrene (Sigma). Transduced
cells were enriched for GFP expression (under an internal ribosome entry site)
by multiple rounds of cell sorting using a Vantage SE model fluorescence-
activated cell sorter (BD Biosciences) and maintained at a purity of 
97% as
measured by flow cytometry.
mRNA analysis. For Northern blotting, 15 g of total RNA (RNA-Bee;
Tel-Test, Inc.) was fractionated in agarose-formaldehyde gels, transferred to
nylon membranes (Zeta Probe; Bio-Rad), and hybridized using PerfectHyb Plus
(Sigma). For quantitative real-time RT-PCR (qRT-PCR), 1 g of DNase I-
treated total RNA was used to make random- or oligo(dT)-primed first-strand
cDNA using SuperScript RT (Invitrogen). Expression was measured using
SYBR Green (Applied Biosystems) and an ABI Prism 7000 (Applied Biosys-
tems). Primers were designed using either MacVector (Accelrys Software) or
PrimerBank (63) and are available upon request.
NF-B-dependent reporter gene assay. HEK 293T cells were plated in either
duplicate (in 24-well plates) or triplicate (in 96-well plates) and 24 h later were
transfected with 1 g or 0.33 g total DNA using Lipofectamine 2000 (Invitro-
gen), respectively. Each transfection contained the indicated expression plas-
mids, with 120 ng of 2B-Luc reporter plasmid (34) and 30 ng of control pRL-TK
plasmid (Renilla luciferase; Promega). Twenty-four hours posttransfection, cells
were stimulated for 5 h and lysed in Passive lysis buffer (Promega), and luciferase
was measured using a dual-luciferase reporter assay system (Promega) and a
Monolight 3096 luminometer (BD Pharmingen).
Electrophoretic mobility shift assay. Ten micrograms of nuclear extract was
incubated with IRDye700-labeled DNA probes (LI-COR) for NF-B (Ig 
promoter) or for STAT1/3 (M67) (52). Each reaction included an IRDye800-
labeled Y-box (E promoter) probe to normalize loading to the constitutive
NF-Y complex. Protein-DNA complexes were resolved on 5% gels and imaged
with an Odyssey infrared imaging system (LI-COR).
Immunoprecipitation and Western blotting. For immunoprecipitation, cell
lysates were prepared by freeze-thaw in isotonic buffer containing 0.1% NP-40
and were incubated with anti-Myc-agarose beads (Santa Cruz Biotechnology).
For Western blotting, whole-cell lysates were prepared in boiling sodium dodecyl
sulfate (SDS) lysis buffer (50 mM Tris [pH 7.6], 0.5% SDS, and 2 mM dithio-
threitol). For Western blots coupled to luciferase assays, after preparation of
luciferase lysates, the pellets were solubilized in boiling SDS lysis buffer. Cell
equivalents of soluble and insoluble extracts were acetone precipitated, fraction-
ated, and blotted. Western blots were visualized with Alexa 680-conjugated
(Molecular Probes) or IRDye800-conjugated (Rockland) secondary antibodies
and an Odyssey infrared imaging system (LI-COR). The Myc (9E10), IKK
(FL-419), IB (FL), glycemldehyde-3-phosphate dehydrogenase (GAPDH) (V-
18), and Lamin B1 (C-20) antibodies were obtained from Santa Cruz Biotech-
nology.
Nucleotide sequence accession number. The nucleotide sequences of mouse
ABIN-3, mouse ABIN-3, and human ABIN-3 have been submitted to Gen-
Bank under accession numbers EF585494, EF585495, and EF585496, respec-
tively.
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ABIN-3 expression is induced by IL-10 in LPS-stimulated
macrophages. In order to identify novel IL-10-induced genes
in LPS-stimulated macrophages, we performed RDA using the
mouse monocyte/macrophage RAW264.7 cell line stimulated
with IL-10 plus LPS or with LPS alone. After screening ap-
proximately 500 enriched cDNA fragments, we identified a
novel 200-base pair gene product that was preferentially in-
duced in IL-10 plus LPS-stimulated cells. Using this gene frag-
ment to screen a cDNA library, we isolated full-length clones
that, upon sequence analysis, were found to represent the
mouse ortholog of human LIND, a gene discovered previously
whose expression was induced in human monocytes infected
with Listeria monocytogenes (57). Based on sequence homol-
ogy, LIND has also been termed human ABIN-3, the third
member of the ABIN family of proteins (21).
We confirmed that the combination of IL-10 plus LPS in-
duced the expression of ABIN-3 in mouse macrophages and
tissues. Three ABIN-3-related transcripts were slightly induced
in BMM following LPS stimulation (as detected by Northern
blotting), not induced by IL-10 alone, but were robustly in-
duced by the combination of IL-10 and LPS (Fig. 1A). This
expression pattern was distinct from that of SOCS3, which was
induced by either LPS or IL-10 alone and showed a modestly
enhanced induction by the combined stimuli. Similar results
were obtained using RAW264.7 cells or thioglycolate-elicited
peritoneal exudate macrophages (data not shown). The mod-
est induction of ABIN-3 by LPS stimulation alone was still
observed when BMM from the IL-10-null mouse were tested,
thereby documenting that LPS alone could indeed induce a
low level of expression in the absence of the autocrine action of
IL-10. In vivo, as detected by qRT-PCR, ABIN-3 transcripts
displayed low or undetectable basal expression in tissues from
naive mice but were induced, particularly in myeloid-rich tis-
sues, after mice were injected with the combination of IL-10
and LPS (Fig. 1B).
A schematic of the three mouse ABIN-3 transcripts, indicating
their open reading frames, is presented in Fig. 1C. The three
mRNA species derive from a single gene in mice, Tnip3, and are
generated by way of either alternative splicing (in the case of
the smallest form, referred to hereafter as ABIN-3) or alterna-
tive polyadenylation (in the case of the largest form, referred to
hereafter as ABIN-3Long or ABIN-3L). The mouse ABIN-3 and
ABIN-3L transcripts have identical open reading frames and en-
code the 208-aa ABIN-3 protein isoform. In contrast, the
ABIN-3 splice variant encodes a 197-aa protein that is identical
to mouse ABIN-3 from residues 1 to 140 but has a unique 57-aa
C terminus and 3 untranslated region.
To determine whether ABIN-3 gene expression was also reg-
ulated by IL-10 in humans, the human monocytic cell lines THP-1
and U937 were stimulated with LPS, IL-10, or the combination of
LPS plus IL-10, and ABIN-3 mRNA levels were measured by
FIG. 1. IL-10 induces ABIN-3 gene expression in LPS-stimulated mononuclear phagocytes. (A) BMM from wild-type (Il10/) or IL-10-null
(Il10/) mice were cultured in the absence (media) or presence of LPS (100 ng/ml), IL-10 (20 ng/ml), or LPS plus IL-10 for 2 h. Total RNA was
prepared and analyzed by Northern blotting. (B) 129/Sv mice were injected intraperitoneally with phosphate-buffered saline (PBS) or LPS (250
g) plus IL-10 (5 g). After 2 h, tissue total RNA was prepared and analyzed by qRT-PCR in duplicate, and values normalized to 18S rRNA are
presented as means  standard deviations (SD). SM, skeletal muscle; BM, bone marrow; LN, lymph nodes. (C) Schematic of the mouse ABIN-3
transcripts. The ABIN-3 and ABIN-3L mRNAs are derived by alternative polyadenylation and encode the identical protein, while the ABIN-3
mRNA is derived by alternative splicing and encodes a protein with a distinct C terminus (diamond pattern versus black, respectively) and 3
untranslated region. (D) THP-1 and U937 cells were cultured in the absence (media) or presence of LPS (100 ng/ml), IL-10 (20 ng/ml), or LPS
plus IL-10 for 2 h. Total RNA was analyzed by qRT-PCR and values normalized to GAPDH are presented as means  SD.
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qRT-PCR (Fig. 1D). As was the case with mouse, human ABIN-3
transcripts were induced strongly by IL-10 in the presence of LPS.
Characteristics of ABIN-3 induction: agonist specificity and
requirement for de novo protein synthesis. We assessed the
selectivity of ABIN-3 induction by IL-10 and LPS with mouse
macrophages. First, we determined whether ABIN-3 could be
induced by proinflammatory cytokines that also activate
STAT3 such as IL-6 and type I IFN (IFN-/). Stimulation of
BMM with IL-6 did not lead to the induction of ABIN-3, either
when the cytokine was added alone or in the presence of LPS
(Fig. 2A). In contrast, IL-6 induced the expression of the
SOCS3 and Bcl-3 control genes. Likewise, stimulation of BMM
with IFN-, either alone or in combination with LPS, failed to
induce significant ABIN-3 expression, although IFN- indeed
induced expression of the ISG54 control gene (Fig. 2B). Thus,
ABIN-3 expression is induced selectively in response to IL-10,
relative to proinflammatory cytokines that activate JAK-STAT
pathways including STAT3.
We next tested whether ABIN-3 expression could be in-
duced by IL-10 in the presence of proinflammatory agonists
other than LPS. For this purpose, BMM were stimulated with
IL-10 in the presence of LPS, PGN, double-stranded RNA
[poly(I:C)], unmethylated CpG DNA, IL-1, or TNF. As was
the case for LPS, ABIN-3 expression was induced by IL-10 in
the presence of each of these proinflammatory stimuli (Fig.
2C). Thus, ABIN-3 is an IL-10-regulated gene product that is
induced in macrophages undergoing proinflammatory re-
sponses, i.e., that are being stimulated by TLR, IL-1R, and
TNF receptor agonists.
To characterize the kinetics of ABIN-3 induction, a time
course of stimulation was analyzed by Northern blotting. In
response to IL-10 and LPS, ABIN-3 transcripts were induced
at 1 h, reached maximal levels at 2 h, and began to decline by
6 h (Fig. 2D). ABIN-3 expression was not induced when mac-
rophages were cultured in the presence of the translation in-
hibitor cycloheximide or the transcription inhibitor actinomy-
cin D, indicating that ABIN-3 induction depends on both de
novo protein synthesis and gene transcription (Fig. 2E). This
characteristic is in contrast to the induction of SOCS3, which
occurred independently of de novo protein synthesis. Both of
the ABIN-3 protein isoforms could be detected in stimulated
mouse BMM and displayed induction kinetics that reflected
FIG. 2. ABIN-3 is a delayed-response gene induced selectively by IL-10 in the presence of proinflammatory stimuli. (A) BMM from Il10/
mice were cultured in the absence (media) or presence of LPS (100 ng/ml), IL-10 (10 ng/ml), IL-6 (10 ng/ml or 100 ng/ml) alone or in combination
as indicated for 2 h and analyzed by Northern blotting. (B) Similar to that shown in panel A, except that IFN- was substituted for IL-6. (C) BMM
from wild-type 129/Sv mice were cultured in the absence (media) or presence of IL-10 (20 ng/ml) alone or in combination with LPS (100 ng/ml),
PGN (20 g/ml), poly(I:C) (150 g/ml), CpG DNA [CpG ()] (10 g/ml), non-CpG DNA control [CpG ()] (10 g/ml), IL-1 (10 ng/ml), or
TNF- (10 ng/ml) for 2 h and analyzed by qRT-PCR in duplicate. Expression was normalized to 18S rRNA, and values are presented as means 
standard deviations (SD). (D) BMM were cultured in the presence of LPS (100 ng/ml) together with IL-10R1-neutralizing MAb (10 g/ml) or
with IL-10 (20 ng/ml) and analyzed by Northern blotting. (E) BMM were cultured with LPS (100 ng/ml) plus IL-10 (20 ng/ml) for 2 h, in either
the absence or the presence of cycloheximide (CHX; 10 g/ml) or actinomycin D (Act.D; 10 g/ml), and analyzed by Northern blotting. (F) BMM
were cultured for the indicated times in the presence of LPS (100 ng/ml) plus IL-10 (20 ng/ml), and total cell lysates were analyzed by Western
blotting. Equivalent amounts of in vitro-translated proteins (empty vector, ABIN-3, or ABIN-3) were loaded as controls.
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that of their mRNAs. The cellular ABIN-3 protein disap-
peared more rapidly than the ABIN-3 isoform, suggesting that
the former was less stable (Fig. 2F). These data collectively
characterize ABIN-3 as a delayed response gene downstream
of the combined IL-10 and TLR/IL-1/TNF stimulation in mac-
rophages.
ABIN-3 is not required for IL-10’s anti-inflammatory ac-
tions or NF-B regulation in mice. In view of the selective
regulation of ABIN-3 by IL-10 and the fact that other ABIN
family members (namely, ABIN-1 and ABIN-2) were charac-
terized as NF-B inhibitors in overexpression studies, we
tested whether mouse ABIN-3 was required for IL-10’s anti-
inflammatory actions by generating ABIN-3 knockout mice
(Fig. 3). The gene that encodes ABIN-3 (Tnip3) is located on
mouse chromosome 6 and comprises 8 exons. Our gene-tar-
geting strategy deleted exons 1 to 5, which includes all of the
N-terminal sequence shared between ABIN-3 and ABIN-3,
as well as the C-terminal sequence specific to ABIN-3 (Fig.
3A). Wild-type (/), heterozygous (/), and homozygous
(/) ABIN-3 knockout mice were identified by restriction
fragment length polymorphism/Southern blotting (Fig. 3B).
ABIN-3-null mice were born in the expected Mendelian dis-
tribution (70 wild type:140 heterozygous:91 knockout) and
were fertile. BMM from ABIN-3-null mice expressed neither
FIG. 3. ABIN-3-null macrophages and mice display normal responses to IL-10 and LPS. (A) Schematic of the mouse ABIN-3 locus (Tnip3),
the gene targeting vector, and the disrupted allele with relevant features indicated, including the neomycin resistance (Neo) cassette flanked by
loxP sites (black triangles), the thymidine kinase (TK) cassette, and the external Southern blotting probes. (B) Southern blotting of XbaI-digested
genomic DNA from wild-type (/) mice and mice heterozygous (/) or homozygous (/) for the mutant Tnip3 allele, using a 5 external
probe. (C) Western blotting with ABIN-3-specific MAb demonstrating a lack of protein expression in Tnip3/ BMM stimulated with LPS (100
ng/ml) and IL-10 (20 ng/ml). (D) Wild-type (Tnip3/) or ABIN-3-null (Tnip3/) BMM were stimulated with LPS (100 ng/ml) alone or in the
presence of IL-10 (10 ng/ml) for the indicated times, and total RNA was analyzed by qRT-PCR in duplicate. Values are normalized to 18S rRNA
and presented as means  standard deviations. (E) BMM were mock stimulated (gray histograms) or stimulated with IFN- (10 ng/ml) or IFN-
plus LPS (100 ng/ml) (dashed lines) in the absence or presence of IL-10 (10 ng/ml) (solid lines). Surface levels of ICAM-1, I-Ab, or CD86 were
measured by flow cytometry. (F) Tnip3/ (n 6) and Tnip3/ (n 6) mice were injected intraperitoneally with LPS as indicated and monitored
daily.
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ABIN-3 transcripts nor proteins when tested before or after
stimulation (Fig. 3C and D and data not shown).
In contrast to mice that lack IL-10 responses, ABIN-3-null
mice displayed no clinical phenotype. IL-10-null mice develop
spontaneous enterocolitis within the first few months of age,
with a disease severity that is dependent on the genetic back-
ground of the gene-targeted mouse (129/Sv and BALB/c mice
display greater severity than C57BL/6 mice) (3, 28, 56, 59).
Associated with the inflammatory disease, the peripheral my-
eloid and lymphoid cells from IL-10-null mice display a hyper-
active phenotype compared to control cells (28, 59). In con-
trast, our ABIN-3-null mice, generated and maintained on the
susceptible 129/Sv genetic background, did not develop spon-
taneous inflammatory or autoimmune disease. ABIN-3-null
mice developed normally, exhibited normal tissue and organ
architecture, and showed no signs of inflammatory disease
even when monitored up to 18 months of age (data not shown).
Furthermore, ABIN-3-null mice displayed normal levels and
activation status of peripheral lymphoid and myeloid cells.
To directly test whether mouse ABIN-3 was required for the
anti-inflammatory effects of IL-10 on macrophages in vitro, we
compared proinflammatory gene induction in BMM from mice
with an intact versus a disrupted ABIN-3 gene. IL-10 produced
the same suppressive effects on LPS-induced proinflammatory
gene expression in macrophages from ABIN-3-null mice as it
did from wild-type mice (Fig. 3D). ABIN-3-null macrophages
did not exhibit quantitatively or kinetically enhanced responses
to LPS signaling in the absence or presence of IL-10 compared
to that of wild-type macrophages. Moreover, IL-10 responses
in ABIN-3-null macrophages were equivalent to those of wild-
type macrophages throughout a wide dose range of cytokine
and LPS (data not shown). Additionally, no differences were
observed for either LPS- or TNF--dependent activation of
NF-B or for the induction of classical NF-B IB and A20
target genes (data not shown). Last, IL-10-mediated suppres-
sion of LPS and/or IFN--induced surface expression of major
histocompatibility class II (I-Ab), B7-2 (CD86), and intercel-
lular adhesion molecule (ICAM)-1 was also unaltered in
ABIN-3-null macrophages (Fig. 3E). Similar results were ob-
tained when elicited peritoneal exudate macrophages were ex-
amined (data not shown).
To test whether ABIN-3 deficiency led to discernible effects
on IL-10 responses in vivo, we assessed the susceptibility of
ABIN-3-null mice in three disease models for which IL-10 is
known to play a critical role. Compared to wild-type mice,
IL-10-null mice exhibit increased sensitivity to endotoxin shock
(4), increased susceptibility to experimental colitis induced by
oral administration of dextran sulfate sodium (60), and in-
creased resistance to infection with microbial pathogens in-
cluding Listeria monocytogenes (11, 39). However, when they
were tested in these same models, no differences could be
detected between ABIN-3-null mice and wild-type mice (Fig.
3F and data not shown). Taken together, these results indicate
that ABIN-3 is not an essential mediator of IL-10’s broad
anti-inflammatory actions in mice and, moreover, that it does
not appear to play an obligatory role in the negative regulation
of NF-B or other proinflammatory signaling pathways.
Functional divergence in mouse and human ABIN-3 for
NF-B inhibition. The aforementioned experiments were
complemented by testing whether enforced expression of
ABIN-3 was sufficient to effect NF-B inhibition akin to that of
ABIN-1 and ABIN-2. Using a reporter gene assay, HEK 293T
cells transfected with an NF-B-dependent luciferase gene ex-
pressed luciferase in response to TNF stimulation (Fig. 4A).
This induction was completely inhibited by the coexpression of
mouse A20 protein and partially inhibited by coexpression of
mouse ABIN-1 or mouse ABIN-2. In contrast, enforced ex-
pression of mouse ABIN-3 (mABIN-3) or mABIN-3, singly
or in combination, had no effect on NF-B activation (Fig. 4A
and data not shown). The lack of activity of mouse ABIN-3
could not be explained simply by a deficit of protein expression
since the Myc epitope-tagged mouse ABIN-3 was present at
levels comparable to or higher than those of the functional
Myc-tagged ABIN family members (Fig. 4A, right panel).
Mouse ABIN-3, which also did not inhibit NF-B, was not
significantly expressed in the transfected cells, confirming its
relative instability. In contrast, enforced expression of
hABIN-3 inhibited NF-B activation in a manner similar to
that of ABIN-1 and ABIN-2 (Fig. 4A). The inhibitory activity
of human ABIN-3 was dose dependent (i.e., dependent on
protein expression level) and was generalizable to IL-1-in-
duced NF-B activation as well (Fig. 4B).
We next addressed whether enforced expression of human
ABIN-3 was sufficient to inhibit TLR-induced NF-B activa-
tion. As TLRs diverge in their usage of specific TIR-containing
adaptor proteins for signaling (1), we tested the effect of hu-
man ABIN-3 against a representative group of receptors which
included TLR2, TLR3, and TLR4. Notably, human ABIN-3
inhibited LPS-induced NF-B activation in HEK 293T cells
engineered to express the TLR4 receptor complex (Fig. 4C).
Likewise, enforced expression of human ABIN-3 inhibited
TLR2- and TLR3-induced NF-B activation. In contrast,
mouse ABIN-3 or ABIN-3 failed to inhibit TLR-induced
NF-B activation. Collectively, these results demonstrate that
although ABIN-3 represents an IL-10-inducible gene in both
humans and mice, only the human protein is capable of sup-
pressing proinflammatory signaling pathways leading to canon-
ical NF-B activation.
Functional divergence correlates with genetic divergence:
mouse ABIN-3 lacks the ABIN homology domain. Human
ABIN proteins share only a short stretch of protein sequence
homology, referred to as the ABIN homology domain (AHD).
The AHD consists of two homologous stretches of approxi-
mately 20 amino acids each, separated by a stretch of approx-
imately 30 nonhomologous amino acids (21, 61). The two ho-
mologous subregions within the AHD have been designated
AHD1 and AHD2 (21). Deletion of the entire AHD from
ABIN-1 or ABIN-2 or site-directed mutagenesis within the
AHD2 subdomain of ABIN-1 renders the proteins incapable
of inhibiting NF-B (21, 36). These results point to a critical
role for the AHD and specifically the AHD2 sequence in
mediating the ability of ABINs to inhibit NF-B. The AHD1
subdomain, on the other hand, plays a functional role in me-
diating the ability of ABINs to interact with A20. Thus, the
AHD1 and AHD2 subdomains appear to mediate distinct
ABIN activities.
Sequence alignment of the functionally divergent human
and mouse ABIN-3 proteins revealed that the mouse protein
lacks 92 amino acids present within the C terminus of human
ABIN-3. Consequently, mouse ABIN-3 is devoid of all but the
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five most N-terminal residues of the AHD2 subdomain (Fig.
5A). In humans, this specific sequence is derived from three
genomic exons that are not present in the mouse gene (Fig.
5C). Alternatively, both the mouse and human ABIN-3 splice
variants display even greater deficits in the ABIN homology
domain because both lack approximately half of AHD1 and all
of the intervening and AHD2 sequences. In both species,
ABIN-3 arises as a consequence of analogous alternative
splicing of the ABIN-3 gene. Despite this equivalent process-
ing, the encoded C-termini of the human and mouse ABIN-3
proteins are distinct due to a lack of sequence conservation
within the corresponding region of exon 5 between the human
and mouse genes (Fig. 5B and C).
We have not been able to identify, through either bioinfor-
matic or experimental means, a mouse ABIN-3 transcript that
contains a human-like insertion sequence containing the
AHD2, nor have we been able to identify a human ABIN-3
splice variant that lacks all or part of the 92-amino-acid inser-
tion sequence and AHD2 analogous to the mouse ortholog. An
examination of publicly available genome sequences revealed
that the rat ABIN-3 ortholog was similar to the mouse (i.e., it
lacks the human-like AHD2-containing sequence), while
ABIN-3 from chimpanzee, cow, dog, and chicken were similar
to the human protein (Fig. 5D).
The ABIN homology domain is required but not sufficient
for human ABIN-3 function. We performed structure-function
analyses to address whether the functional divergence between
human and mouse ABIN-3 was due to the presence or absence
of the intact AHD. Deletion of AHD1, AHD2, or the entire
AHD from human ABIN-3 had no deleterious effect on the
expression or stability of the protein (Fig. 6A). Nonetheless,
the ability of human ABIN-3 to inhibit NF-B activity was
partially impaired by deletion of AHD1 and completely abro-
gated by deletion of either AHD2 or the entire AHD. These
latter two human mutants functionally resembled mouse
ABIN-3, which naturally lacks the AHD2 sequence (Fig. 6B).
Thus, the presence of the intact AHD is required for the
anti-inflammatory effects of human ABIN-3 and is sufficient to
account for the functional disparity between the human and
mouse proteins.
FIG. 4. Expression of human ABIN-3, but not mouse ABIN-3, inhibits NF-B activation in response to TNF, IL-1, and TLR signaling.
(A) NF-B-dependent luciferase assay with HEK 293T cells cotransfected in duplicate with the indicated expression plasmids and cultured in the
absence (media) or presence of TNF- (20 ng/ml) for 5 h. (Left panel) Normalized luciferase activity is presented as means  standard deviations.
(Right panel) Western blotting monitoring transfected protein expression. (B) Similar to panel A, except that cells were transfected with a dose
range of hABIN-3 expression plasmid and cultured in the absence (media) or presence of TNF- (20 ng/ml) or IL-1 (20 ng/ml). (C) Similar to
panel A, except that cells were cotransfected with plasmids for the TLR4 receptor complex, TLR2, or TLR3 and cultured in the absence (media)
or presence of LPS (500 ng/ml), PGN (40 g/ml), or poly(I:C) (150 g/ml) for 5 h.
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We next addressed whether mouse ABIN-3 could be con-
verted into a functional protein by generating a mouse-human-
mouse chimera containing the 92-amino-acid insertion se-
quence of human ABIN-3 that includes AHD2 (Fig. 5A and
Fig. 6C). Although this chimeric protein was expressed at suf-
ficient levels relative to that of human ABIN-3, it was still
incapable of inhibiting NF-B activation as measured by the
reporter gene assay (Fig. 6C and D). In this chimeric protein,
the first 5 residues of AHD2 (WHKQQ) were derived from a
mouse sequence while the more C-terminal 18 residues were
derived from human (Fig. 5A and Fig. 6C). We considered the
possibility that the inactivity of the chimeric protein was due to
a species-specific incompatibility in the AHD2. Therefore, us-
ing site-directed mutagenesis, we generated another chimera
with an entirely humanized AHD2. However, this second chi-
meric protein (chimera WH
VL) was yet again not capable of
inhibiting NF-B (Fig. 6C and D). Collectively, these data
demonstrate that whereas the presence of the AHD2 sequence
is required for human ABIN-3 to inhibit NF-B activation, its
incorporation into the mouse protein is not sufficient to impart
human ABIN-3-like activity. Theses results suggest that addi-
tional nonhomologous sequences between human and mouse
contribute to ABIN-3 function.
Enforced expression of human ABIN-3 suppresses proin-
flammatory gene responses. To extend our findings using the
reporter gene assay, we constitutively expressed human
ABIN-3 in the human THP-1 monocytic cell line and examined
proinflammatory gene responses. Enforced expression of Myc
epitope-tagged human ABIN-3 was confirmed by Western
blotting and qRT-PCR, and its expression level was found to
be comparable to that of the endogenous gene induced by LPS
and IL-10 (data not shown). Compared to that of control cells,
THP-1 cells stably expressing human ABIN-3 displayed par-
tially impaired induction of several proinflammatory NF-B-
dependent genes in response to LPS or PGN (Fig. 7). The
mRNA levels for IL-8, TNF-, IL-12p40, and IL-6 were sup-
pressed at multiple time points after stimulation (Fig. 7A), or
when various doses of ligand were employed (Fig. 7B). The
magnitude of the suppression of proinflammatory gene induc-
tion in human ABIN-3-expressing THP-1 cells was comparable
to that of NF-B inhibition observed for the reporter gene
assays (Fig. 4). The effect of human ABIN-3 was both gene-
and stimulus-specific as there was no suppression of IFN--
induced IRF-1 or IL-10-induced SOCS3 expression (Fig. 7C).
These data support the notion that human ABIN-3 expression
FIG. 5. Mouse ABIN-3 lacks a complete ABIN homology domain. (A) Protein sequence alignment of human and mouse ABIN-3. AHD1 and
AHD2 subdomains of human ABIN-3 are shown. (B) Protein sequence alignment of human and mouse ABIN-3, focusing on their unique  splice
variant-specific C-terminal sequences starting at aa 165 of human and aa 140 of mouse. (C) Schematic alignment of the human and mouse ABIN-3
genes. Gene and intron lengths are drawn to scale, while exons (boxes) are shown enlarged but relative in size to one another. Arrowheads and
asterisks indicate the translation initiation and termination sequences, respectively. Dotted lines indicate homologous exons. Exon regions that give
rise to AHD1 and AHD2 are shaded black, while exon 5 regions specific to the ABIN-3 splice variants are white. (D) Protein sequence alignment
of ABIN-3 from multiple species corresponding to the region surrounding the AHD.
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suppresses NF-B-dependent proinflammatory gene induc-
tion.
Human ABIN-3 acts upstream of IKK activation to inhibit
NF-B signaling. To explore the mechanism by which human
ABIN-3 expression inhibits NF-B activity, we first examined
whether it had an effect on NF-B nuclear translocation and/or
DNA binding. THP-1 cells stably expressing human ABIN-3
displayed reduced levels of nuclear NF-B DNA-binding ac-
tivity when stimulated with LPS or PGN as measured by elec-
trophoretic mobility shift assay (EMSA) (Fig. 8A, upper
panel). This effect correlated with reduced degradation of cy-
toplasmic IB as measured by Western blotting (Fig. 8A,
lower panel). The partially impaired IB degradation and
NF-B activation led to a reduction in the NF-B-dependent
resynthesis of IB at the later time points. A similar partial
reduction in nuclear NF-B DNA-binding activity and IB
degradation was observed when measured at a fixed time point
using a dose range of the TLR agonists (Fig. 8B). In agree-
ment with our finding that human ABIN-3 had no effect on
IFN-- or IL-10-induced gene expression (Fig. 7C), we ob-
served no inhibitory effect on the activation of STAT1 or
STAT3 (Fig. 8C).
These results indicate that human ABIN-3 acts in the cyto-
plasm to suppress IB degradation. This notion is consistent
with both the cytoplasmic localization of the ABIN-3 protein and
the mechanisms of action reported for ABIN-1 and ABIN-2 (20,
61 and data not shown). In order to confirm this concept for
human ABIN-3, additional epistatic experiments were carried out
in which NF-B was activated in a ligand-independent manner by
overexpressing individual pathway components (Fig. 9A). Over-
expression of TLR4, RIP1, or TRAF6 in HEK 293T cells led to
the activation of NF-B-dependent luciferase, which could be
inhibited by human ABIN-3 coexpression in an AHD2-depen-
dent manner. In contrast, human ABIN-3 was unable to inhibit
NF-B activation in response to the overexpression of either
IKK or RelA. These results indicate that human ABIN-3 acts
upstream of the IKK kinase. The regulatory subunit of the IKK
complex, IKK (also termed NEMO), is an attractive candidate
for the target of human ABIN-3’s actions since it is shared among
all pathways leading to IKK and canonical NF-B activation (6,
18). In agreement with this reasoning, ABIN-2 (and more re-
cently ABIN-1) has been shown to physically interact with IKK
(36, 37). To determine whether human ABIN-3 could likewise
interact with IKK, Myc epitope-tagged versions of human
ABIN-3, mouse ABIN-3, or mouse ABIN-2 were coexpressed
with human IKK in cells and protein-protein interaction was
assessed by coimmunoprecipitation (Fig. 9B). The results con-
firmed that human ABIN-3 associates with IKK in a stimulus-
independent manner and to a similar extent as that of the mouse
ABIN-2 control. Collectively, these data suggest that expression
of human ABIN-3 acts to inhibit activation of the IKK complex
through an interaction with IKK. However, interaction with
IKK is not sufficient to fully account for the inhibitory action of
human ABIN-3 since the noninhibitory mouse ABIN-3 also co-
immunoprecipitated IKK (Fig. 9B). Thus, the precise mecha-
nism by which an ABIN-IKK interaction might productively
lead to suppression of IB kinase activation remains to be eluci-
dated.
DISCUSSION
In this study, we identified ABIN-3 as a gene induced by
IL-10 in mononuclear phagocytes coordinately responding to
proinflammatory stimuli. Previously, the two other known
FIG. 6. The ABIN homology domain is required for human
ABIN-3 to inhibit NF-B. (A) Left panel shows a diagram of human
ABIN-3 deletion mutants. 	AHD1 lacks aa 152 to 172, 	AHD2 lacks
aa 199 to 221, and 	AHD lacks aa 152 to 221. Right panel shows
Western blotting of the mutants expressed in HEK 293T cells. (B) NF-
B-dependent luciferase assay with HEK 293T cells cotransfected in
duplicate with plasmids for the TLR4 complex and the indicated
ABIN-3 expression plasmids. Cells were cultured in the absence (me-
dia) or presence of TNF- (20 ng/ml) or LPS (500 ng/ml) for 5 h.
Normalized luciferase activity is presented as means  standard devi-
ations. (C) Left panel shows a schematic of mouse-human-mouse
ABIN-3 chimera constructs. The chimera has aa 204 to 295 of
hABIN-3 inserted between aa 178 and 179 of mABIN-3. Chimera
WH
VL has had the W174/H175 aa of mouse changed to match the
V199/L200 aa of human ABIN-3. Right panel shows Western blotting
of the chimeras expressed with HEK 293T cells. (D) NF-B-dependent
luciferase assay as described in panel B.
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ABIN family members, ABIN-1 and ABIN-2, were character-
ized as a consequence of their interaction with the NF-B
negative feedback regulator, A20, and, in vitro, were shown to
inhibit NF-B activation in their own right (20, 61). Although
the role of A20 in negative regulation of NF-B has been
firmly established (7, 33), the significance of its interaction with
ABIN family members and the physiologic roles of the ABINs
in regulating NF-B are presently unclear. In contrast to A20,
the expression of ABIN-1 and ABIN-2 are not under the con-
trol of NF-B and so they do not readily fit into an analogous
model of negative feedback. Moreover, whereas ABIN-1-null
mice have not yet been reported, studies with ABIN-2-null
mice and cells have failed to demonstrate a role for ABIN-2 in
the negative regulation of NF-B. Instead, ABIN-2 appears to
serve a positive signaling role in TLR-induced activation of the
Tpl2-ERK pathway (32, 45). Therefore, our discovery that
ABIN-3 was unique among ABINs in its induction by IL-10
prompted our pursuit of its potential role as a mediator of
IL-10’s anti-inflammatory actions.
Through the generation and analysis of ABIN-3-null mice
and macrophages, we conclude that mouse ABIN-3 does not
play an obligatory role in mediating the broad anti-inflamma-
tory effects of IL-10. Furthermore, mouse ABIN-3 does not
play a major role in the normal negative regulation of NF-B
or other proinflammatory signaling pathways. ABIN-3-null
mouse macrophages responded by producing proinflammatory
molecules in a manner that was indistinguishable from wild-
type macrophages. ABIN-3 deficiency did not lead to an alter-
ation in the magnitude or kinetics of NF-B activation or
NF-B-dependent gene expression in mice. Importantly,
ABIN-3-null macrophages responded normally to IL-10, and
ABIN-3-null mice did not develop the autoimmune and in-
flammatory phenotype observed with mice that lack IL-10 re-
sponses.
In parallel with our studies investigating the requirement for
ABIN-3 in promoting IL-10’s actions or in regulating NF-B
signaling in mice, we questioned whether ABIN-3 expression
was sufficient to mediate IL-10 or ABIN-like anti-inflamma-
tory effects. Consistent with our analysis of ABIN-3-null mice,
enforced expression of either isoform of mouse ABIN-3 (i.e.,
ABIN-3 or ABIN-3) was not sufficient to inhibit NF-B trans-
activation. In striking contrast, enforced expression of the hu-
man ABIN-3 ortholog in cells inhibited NF-B activation and
proinflammatory gene expression in response to TNF, IL-1,
and TLR ligands. As the manuscript was being prepared, a
report from Wullaert et al. appeared in press showing that
human ABIN-3 was an LPS-inducible gene and that its en-
forced expression could inhibit NF-B activation (68). Our
study confirms and significantly extends the concurrent work of
Wullaert et al. by demonstrating the important role of IL-10 in
regulating ABIN-3 gene expression, characterizing the species-
specific differences that exist for this gene, and unequivocally
documenting the lack of anti-inflammatory function for mouse
ABIN-3 in vivo.
The functional differences that we document herein between
the mouse and the human proteins reflect the structural dif-
ferences between the two. Human ABIN-3 contains a com-
plete ABIN homology domain, while the mouse ortholog does
FIG. 7. Enforced expression of human ABIN-3 in human monocytic cells suppresses proinflammatory gene expression. (A) THP-1 cells
transduced with empty vector or those stably expressing hABIN-3 were cultured in the presence of LPS (100 ng/ml) or PGN (10 g/ml) for the
indicated time, and total RNA was analyzed by qRT-PCR in duplicate. Values are normalized to GAPDH and are presented as means  standard
deviations. (B) Similar to panel A, except that cells were treated for 45 min with the indicated doses of LPS or PGN. (C) Similar to panel A, except
that cells were treated with IFN- (25 ng/ml) or IL-10 (25 ng/ml).
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not. Deletion of the AHD2 subdomain of human ABIN-3
renders it incapable of inhibiting NF-B. Therefore, the ab-
sence of the AHD2 in mouse ABIN-3 is sufficient to explain its
functional inactivity. However, introducing the AHD2 se-
quence of human ABIN-3 into the mouse ortholog was not
sufficient to impart NF-B inhibitory capacity to mouse
ABIN-3. These results suggest that additional ABIN-3 se-
quences may have functional importance in inhibiting NF-B.
It is noteworthy that the genetic and structural differences
between mouse and human ABIN-3 are reflected in other
species. Rat ABIN-3 resembles the mouse ortholog in that it
also lacks an intact AHD. In contrast, ABIN-3 of chicken, dog,
cow, and chimpanzee contain an intact AHD similar to the
human ortholog. This species divergence in ABIN-3 may ulti-
mately impact the ways in which different host species respond
to inflammatory signals.
Although the mechanisms by which IL-10 manifests its anti-
inflammatory effects remain incompletely understood, there is
generalized agreement that STAT3 is integral in mediating
IL-10 function. In contrast, the question of whether IL-10 acts
to inhibit NF-B activation has been a matter of debate (16,
67). Part of the disagreement may stem from the use of varied
experimental conditions or could reflect a true heterogeneity
of effector mechanisms downstream of IL-10-induced STAT3
activation that differ between cell types and/or species. Reports
suggesting a role for IL-10 in inhibiting NF-B have pointed to
multiple and distinct mechanisms of action. IL-10 has been
shown to inhibit IKK activation in the cellular cytoplasm while
also inhibiting NF-B transactivation potential in the nucleus
(14, 53, 54). Evidence for the former stems primarily from
work using human mononuclear phagocytes (53, 54, 62),
whereas evidence for the latter mechanism stems from studies
using both human and mouse cells (14, 30, 53).
Herein, we provide evidence that IL-10-induced human
ABIN-3 can mediate anti-inflammatory effects in the cyto-
plasm by inhibiting the activation of the IKK kinase, thus
preventing the degradation of IB. The IKK regulatory sub-
unit IKK may be a target of human ABIN-3 since it is re-
quired for IKK activation and could associate with human
ABIN-3 when coexpressed in cells. In this regard, IL-10 induc-
tion of ABIN-3 in inflammatory human macrophages might
terminate NF-B signaling at a point upstream of IKK activa-
tion in a manner comparable to the negative feedback actions
of A20. Moreover, since our results show that human, but not
mouse, ABIN-3 is structurally competent to exert this activity,
they establish a novel mechanism that could underlie species-
specific differences in the mechanism of action of IL-10.
Research by many groups has led to an emerging picture
wherein IL-10 mediates its broad effects through the induction
of numerous target genes. Some of these genes play essential
roles in mediating highly selective IL-10-induced effects. For
example, the IL-10-induced IB proteins Bcl-3 and IBNS
appear to act as selective transcriptional corepressors at the
level of individual NF-B target gene promoters. At least in
FIG. 8. Enforced expression of human ABIN-3 in human monocytic cells suppresses NF-B activation. (A) THP-1 cells transduced with empty
vector or stably expressing human ABIN-3 were cultured in the presence of LPS (100 ng/ml) or PGN (10 g/ml). Nuclear and cytoplasmic extracts
were prepared at the indicated time and analyzed by EMSA for NF-B activity (upper panels) or by Western blotting for IB degradation (lower
panels). NF-Y and -actin served as loading controls. (B) Similar to panel A, except that cells were treated for 30 min with the indicated doses
of LPS or PGN. (C) Similar to panel A, except that cells were treated with IFN- (25 ng/ml) or IL-10 (25 ng/ml), and nuclear extracts were analyzed
by EMSA for STAT1 or STAT3 activation, respectively.
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mice, Bcl-3 participates in IL-10-mediated suppression of
TLR-induced TNF- synthesis, whereas IBNS appears to
modulate TLR-induced IL-6 and IL-12p40 transcription (22,
29, 30). In addition to antagonizing NF-B, IL-10 mediates yet
broader effects including destabilization and translational in-
hibition of specific cytokine and chemokine mRNAs. Several
other IL-10-induced genes have been shown or suggested to be
important for select IL-10-mediated effects, but to date, abla-
tion of any gene in isolation has not led to an abrogation of all
of IL-10’s anti-inflammatory effects (5, 16, 48, 67). These data
lend support to two models of IL-10 action subsequent to its
activation of STAT3: one involving the induction of heteroge-
neous effector pathways with distinct proinflammatory target
gene specificities and a second involving the induction of re-
dundant mechanisms for the suppression of particular target
genes.
Our data support the concept that IL-10 mediates its anti-
inflammatory effects on mononuclear phagocytes through one
or more of its induced gene products and that one of the
cytokine’s effects might be the attenuation of NF-B signaling.
We raise the possibility that this latter aspect is species specific
due to structural differences in the IL-10-induced ABIN-3
gene. Future studies should address whether ABIN-3 plays an
obligatory role in IL-10-mediated attenuation of NF-B sig-
naling in human mononuclear phagocytes and, if so, whether
its ablation leads to impairment of the anti-inflammatory ef-
fects of IL-10. Our current attempts to ablate ABIN-3 expres-
sion in human mononuclear phagocytes using RNA interfer-
ence (RNAi), employing both small interfering RNAs
transiently and short hairpin RNAs stably, have not yet yielded
sufficient reduction in gene expression to answer these ques-
tions in an unequivocal manner. Nevertheless, the work de-
scribed herein identifies human ABIN-3 as a potential effector
of IL-10’s anti-inflammatory effects in humans.
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